Investigation Report on China's Glimepiride Market 2015-2019

Aug 17, 2015, 08:10 ET from Research and Markets

DUBLIN, Aug. 17, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/3kh2jn/investigation) has announced the addition of the "Investigation Report on China's Glimepiride Market, 2010-2019" report to their offering.

Sulfonylurea has been developed into an important part of an oral antidiabetic drug ever since its first generation came into the market in 1956. As an insulin secretagogue, sulfonylurea directly acts on sulfonylurea receptor on the cell membrane of pancreatic beta cells, stimulates the release of insulin and enhances postprandial elevated blood sugar's excitation upon insulin release. Currently, glimepiride is the best-selling product of sulfonylurea in the Chinese market.

First developed and marketed by Dr. Willmar Schwabe Gmbh Co. KG under the trade name of Amaryl in 1995, glimepiride has been approved by FDA as an oral drug that can be used alone or together with insulin. Ever since Aventis introduced glimepiride into China under the trade name of Amaryl in 2001, about 30 enterprises have got the approval to produce it.

Glimepiride can also sensitize beta cells to insulin, ameliorate insulin resistance and it works best outside prancreas. By increasing glucose transporter (GLUT1 and GLUT2), glimepiride can recover glucose absorption so as to maintain the normal level of blood sugar. Characterized by small dose, few side effects, wide application and low rate of hypoglycemia, glimepiride can treat insulin secretion deficiency, recover glucose absorption and relieve hyperinsulinemia.

According to this market survey, in 2014, Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd took up a market share of about 86% for sales value and Sanofi occupied nearly 90% of the glimepiride market in China if Aventis (Italy)'s 3.8% is counted too. The rest market share were occupied by such companies like Wanbang Biopharmaceuticals, Zhongnuo Pharma and Tianan Pharmaceutical. The sales value of glimepiride in sample hospitals was CNY 224 million in 2014 and CAGR reached 30.7% during the period of 2005-2014.

Key Topics Covered:

1 Related Concepts of Glimepiride

2 Market Profile of Glimepiride in China

3 Survey on Sales Status of Glimepiride in China, 2010-2014

4 Survey on Market Share of Major Manufacturers of Glimepiride in China, 2010-2014

5 Survey on Dosage Forms of Glimepiride in China, 2010-2014

6 Reference Price of Glimepiride in Chinese Hospitals in 2014

7 Major Manufacturers of Glimepiride in Chinese Market, 2010-2014

8 Market Outlook of Glimepiride in China, 2015-2019

Companies Mentioned

- Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd - Aventis(Italy) - Wanbang Biopharmaceuticals - Zhongnuo Pharma - Tianan Pharmaceutical - Guangzhou Hairui Pharmaceutical Co., Ltd

For more information visit http://www.researchandmarkets.com/research/3kh2jn/investigation

Media Contact:

Laura Wood , +353-1-481-1716, press@researchandmarkets.net

 

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com